Riken Vitamin Co., Ltd. (TYO:4526)
Japan · Delayed Price · Currency is JPY 3,215.00
0.00 (0.00%)
Aug 12, 2026, 3:30 PM JST
Riken Vitamin Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 98,176 | 96,300 | 95,582 | 91,484 | 88,750 | 79,231 | |
Revenue Growth | 3.11% | 0.75% | 4.48% | 3.08% | 12.01% | 1.94% |
Cost of Revenue | 68,041 | 66,532 | 64,312 | 61,598 | 61,506 | 53,666 |
Gross Profit | 30,135 | 29,768 | 31,270 | 29,886 | 27,244 | 25,565 |
Selling, General & Admin | 18,994 | 18,510 | 18,612 | 16,941 | 16,638 | 16,007 |
Research & Development | 3,990 | 3,990 | 3,642 | 3,315 | 3,220 | 2,992 |
Operating Expenses | 23,350 | 22,866 | 22,545 | 20,514 | 20,117 | 19,723 |
Operating Income | 6,785 | 6,902 | 8,725 | 9,372 | 7,127 | 5,842 |
Interest Expense | -109 | -114 | -123 | -112 | -132 | -178 |
Interest & Investment Income | 782 | 818 | 874 | 671 | 536 | 448 |
Currency Exchange Gain (Loss) | 45 | -128 | -230 | 267 | 42 | 82 |
Other Non Operating Income (Expenses) | 214 | 224 | 170 | 96 | 150 | 102 |
EBT Excluding Unusual Items | 7,717 | 7,702 | 9,416 | 10,294 | 7,723 | 6,296 |
Gain (Loss) on Sale of Investments | 2,662 | 2,563 | 4,055 | 2,090 | 184 | 14,127 |
Gain (Loss) on Sale of Assets | -89 | -88 | 295 | 3 | - | - |
Asset Writedown | -200 | -174 | -260 | -558 | -57 | -174 |
Other Unusual Items | 237 | 239 | -801 | 78 | 7 | 64 |
Pretax Income | 10,327 | 10,242 | 12,705 | 11,907 | 7,857 | 20,313 |
Income Tax Expense | 3,244 | 3,204 | 3,314 | 3,149 | 1,440 | -1,285 |
Earnings From Continuing Operations | 7,083 | 7,038 | 9,391 | 8,758 | 6,417 | 21,598 |
Minority Interest in Earnings | -4 | -3 | -3 | -3 | -3 | -16 |
Net Income | 7,079 | 7,035 | 9,388 | 8,755 | 6,414 | 21,582 |
Net Income to Common | 7,079 | 7,035 | 9,388 | 8,755 | 6,414 | 21,582 |
Net Income Growth | -19.95% | -25.06% | 7.23% | 36.50% | -70.28% | - |
Shares Outstanding (Basic) | 29 | 30 | 30 | 33 | 33 | 33 |
Shares Outstanding (Diluted) | 29 | 30 | 30 | 33 | 33 | 33 |
Shares Change | -3.70% | -2.45% | -7.17% | -0.58% | 0.02% | 0.02% |
EPS (Basic) | 241.10 | 238.18 | 310.06 | 268.42 | 195.51 | 657.99 |
EPS (Diluted) | 241.10 | 238.18 | 310.06 | 268.42 | 195.51 | 657.99 |
EPS Growth | -17.80% | -23.18% | 15.51% | 37.29% | -70.29% | - |
Free Cash Flow | - | 1,100 | 3,214 | 7,915 | 5,723 | 3,573 |
Free Cash Flow Per Share | - | 37.24 | 106.15 | 242.66 | 174.45 | 108.93 |
Dividend Per Share | 110.000 | 110.000 | 94.000 | 81.000 | 59.000 | 46.000 |
Dividend Growth | 17.02% | 17.02% | 16.05% | 37.29% | 28.26% | 9.52% |
Gross Margin | - | 30.91% | 32.71% | 32.67% | 30.70% | 32.27% |
Operating Margin | 6.91% | 7.17% | 9.13% | 10.24% | 8.03% | 7.37% |
Profit Margin | 7.21% | 7.31% | 9.82% | 9.57% | 7.23% | 27.24% |
Free Cash Flow Margin | - | 1.14% | 3.36% | 8.65% | 6.45% | 4.51% |
EBITDA | 11,830 | 11,579 | 11,929 | 12,702 | 10,845 | 9,578 |
EBITDA Margin | - | 12.02% | 12.48% | 13.88% | 12.22% | 12.09% |
D&A For EBITDA | 5,045 | 4,677 | 3,204 | 3,330 | 3,718 | 3,736 |
EBIT | 6,785 | 6,902 | 8,725 | 9,372 | 7,127 | 5,842 |
EBIT Margin | - | 7.17% | 9.13% | 10.24% | 8.03% | 7.37% |
Effective Tax Rate | - | 31.28% | 26.08% | 26.45% | 18.33% | - |
Advertising Expenses | - | 948 | 1,208 | 964 | 1,204 | 1,460 |